mFOLFOXIRI
Phase 3Small molecule
mFOLFOXIRI is one of 110 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.
3
Indications
9
Total Trials
4
Active Trials
109
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Camptosar
PfizerPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Decadron
AAspen Global Incorporated
Phase 3
5-Fu
TToray Industries, Inc
Phase 3
Calcium Folinate
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
IBI363
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
BL-M07D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Folfirinox
PPhanes Therapeutics
Phase 3
mFOLFOXIRI
DDominik Paul Modest
Phase 3
Clostridium Butyricum
XXijing Hospital of Digestive Diseases
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colorectal Cancer3 trials
mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer
Unknown status·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT05200299·100 enrolled
Metastatic Colorectal Cancer2 trials
Locally-advanced Rectal Cancer1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mFOLFOXIRI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DDominik Paul Modest